Top Track 250

Chiltern is an international contract research organisation based in Slough that works in 45 counties in the Biopharma industry. It has three specialised business units: Chiltern Biopharma, which carries out clinical trials; Chiltern Oncology, which helps its clients develop new cancer therapies; and Chiltern Source, which is a recruitment business specialising in research clinicians. Led by chairman Nicholas Thornton, 54, and chief executive Jim Esinhart, 52, two acquisitions helped annualised sales rise by 28% to £160.5m in 2014, including the purchase that year of American firm Ockham Development for £31m.

This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.

Company details
CompanyChiltern International Group
ActivityPharmaceutical researcher
Sales £m†160.5
Operating profit £m†22.4
Main shareholdersGalaxy Limited Partnership (representing a consolidated investment group of individuals) (90%), management (10%)

If applicable:

* supplied by Company   † annualised figure   ‡  profit = ebitda